Biohit Oyj
Mekalasi Oy to distribute Biohit Quick Tests in Finland
DGAP-News: Biohit Oyj 2015-05-04 / 10:15 --------------------------------------------------------------------- Biohit Oyj Press Release May 4, 2015 at 11:15 a.m. local time (EEST) Biohit Oyj and Mekalasi Oy have signed an agreement for the distribution of the Biohit Quick Tests in Finland. The agreement is in force immediately. Helicobacter Pylori UFT300 Quick Test is a quick test for the detection of H. pylori from a gastric mucosal biopsy. This quick test has excellent sensitivity and specificity, which together with its speed make it a highly accurate tool for H. pylori diagnostics. ColonView Quick Test is the best diagnostic test for screening of colorectal cancer. This sensitive test detects fecal occult blood derived from both the upper and lower gastrointestinal tract - with improved sensitivity for even small benign lesions (polyps) and cancer precursors (adenomas). The Lactose Intolerance Quick Test is designed for rapid diagnosis of lactose intolerance in a duodenal biopsy. Celiac Disease Quick Test measures tissue transglutaminase (tTG) IgA, IgG and IgM antibodies in serum samples, and negative results exclude celiac disease. This test that is taken from fingertip blood sample will bring substantial savings in healthcare costs while reducing the number of unnecessary endoscopies. CEO Semi Korpela, Biohit Oyj: 'As a growth company, Mekalasi Oy is a natural partner for Biohit in Finland for quick tests.' COO John Ekholm, Mekalasi Oy: 'The Biohit Quick Tests include for example the world's quickest Helicobacter Quick Test as well as the child-friendly Celiac Disease Quick Test that is taken from a fingertip blood sample and the best diagnostic test for screening of colorectal cancer. These fit in the existing domestic distribution network of Mekalasi well.' Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is 'Innovating for Health' - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com Mekalasi in brief Founded in 1952, Mekalasi Oy is a sales and marketing company for healthcare supplies. Mekalasi is a dynamic company that offers a comprehensive range of laboratory and medical products. Mekalasi group also includes the contract manufacturer Plastone Oy that is one of the major suppliers of Mekalasi, but most of the product suppliers are big, international companies. The group is a Finnish, family-owned and it employs more than 100 people. News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-05-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Biohit Oyj Finland ISIN: FI0009005482 End of News DGAP News-Service --------------------------------------------------------------------- 352255 2015-05-04
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden